Table 1.
Clinicopathological characteristics of the endometrial cancer patients included in the study.
| EEC stage I | EEC stage II–IV | USC | |
|---|---|---|---|
| Number of patients | 57 | 12 | 14 |
| Agea (range) | 62 (45–80) | 64 (53–82) | 71 (58–82) |
| Follow-upa (range) | 57 months (6–123) | 45 months (3–71) | 28 months (6–74) |
| Treatment | |||
| Lymphadenectomy | 8 (14%) | 7 (58%) | 12 (86%) |
| Radiotherapy | 15 (26%) | 10 (83%) | 5 (36%) |
| Chemotherapy | – | 3 (25%) | 8 (57%) |
| FIGO stage | |||
| I | 57 (100%) | – | 4 (29%) |
| II | – | 4 (33%) | – |
| III | – | 5 (42%) | 3 (21%) |
| IV | – | 3 (25%) | 7 (50%) |
| Grade | |||
| 1 or 2 | 51 (89%) | 7 (58%) | – |
| 3 | 6 (11%) | 5 (42%) | 14 (100%) |
| Myometrial invasion | |||
| <1/2 | 42 (74%) | 3 (25%) | 6 (43%) |
| ≥1/2 | 15 (26%) | 9 (75%) | 8 (57%) |
| LVSI | |||
| No | 46 (81%) | 3 (25%) | 5 (36%) |
| Yes | 11 (19%) | 9 (75%) | 8 (57%) |
| Recurrenceb | |||
| Yes | 8 (14%) | 6 (55%) | 6 (60%) |
| Distant | 5 (9%) | 6 (55%) | 5 (60%) |
| No | 49 (86%) | 5 (46%) | 4 (40%) |
| EC-related mortality | |||
| Yes | 4 (7%) | 5 (42%) | 8 (57%) |
| No | 53 (93%) | 7 (58%) | 6 (43%) |
LVSI lymphovascular space invasion.
aMedian value reported.
bAnalysis among patients without residual disease only.